In agreement with this recommendation, the FDA6 warns that using ESAs to target Hb >11 g/dL increases the risk of serious cardiovascular events (death, MI, stroke, thromboembolism) and has not shown additional benefit; labels advise using the lowest ESA dose sufficient to reduce RBC transfusions and reducing or interrupting the dose as Hb approaches/exceeds 11 g/dL. The gene discussed is GSTM1; the disease is stroke disorder.